Module Specifications.
Current Academic Year 2024 - 2025
All Module information is indicative, and this portal is an interim interface pending the full upgrade of Coursebuilder and subsequent integration to the new DCU Student Information System (DCU Key).
As such, this is a point in time view of data which will be refreshed periodically. Some fields/data may not yet be available pending the completion of the full Coursebuilder upgrade and integration project. We will post status updates as they become available. Thank you for your patience and understanding.
Date posted: September 2024
| |||||||||||||||||||||||||||||||||||||||||||
|
Coursework Only |
|||||||||||||||||||||||||||||||||||||||||||
|
Description Module aims: This module will give the student an understanding of how recombinant DNA technologies are used to manipulate both cloned genes and host producer cells so that biopharmaceuticals and diagnostic reagents can be safely and stably produced using appropriate cell-based systems. | |||||||||||||||||||||||||||||||||||||||||||
|
Learning Outcomes 1. Select from complex issues in protein engineering and demonstrate a systematic understanding of how these may be addressed whereby recombinant genes are manipulated leading to the generation of recombinant proteins with modified properties. 2. Demonstrate a range of standard and specialised recombinant DNA expression systems and tools that are designed to ensure high-level production of soluble, stable, purifiable and authentic recombinant proteins. 3. Acquire a systematic understanding of addressing complex issues in protein engineering, including protein folding, post-translational modifications, and product stability. 4. Develop a critical awareness of genome engineering, gene knockdown technologies, and other relevant approaches, gaining insights into their applications in producer cell engineering, gene therapy. 5. Explore the applications of recombinant technology in the production of biotherapeutics, including recombinant proteins, monoclonal antibodies, vaccines, and gene therapies. 6. Display initiative and an aptitude for independent research by utilizing contemporary techniques of inquiry to critically evaluate relevant examples of products and methods in the Biopharma and Diagnostic fields, fostering a deep understanding of their strengths and limitations. 7. Explore emerging trends and advancements in recombinant technology and biotherapeutics, such as personalized medicine, gene editing technologies (e.g., CRISPR), and novel delivery systems. 8. Exhibit insightful thinking by critically appraising and analyzing cutting-edge products and methods in the forefront of the biopharmaceutical and diagnostic fields, identifying potential limitations and opportunities for innovation, proposing novel approaches or improvements based on a deep understanding of recombinant DNA technology. | |||||||||||||||||||||||||||||||||||||||||||
All module information is indicative and subject to change. For further information,students are advised to refer to the University's Marks and Standards and Programme Specific Regulations at: http://www.dcu.ie/registry/examinations/index.shtml |
|||||||||||||||||||||||||||||||||||||||||||
|
Indicative Content and Learning Activities
Indicative ContentOverview of the structure and roles of DNA, RNA and protein molecules; Genomes, genome sequencing and molecular biology methods including PCR; Cloning and manipulating DNA sequences; Vectors and hosts for expressing recombinant proteins; Transfection and selection of recombinant cells; Protein engineering strategies -case studies; Antibody engineering strategies -case studies; RNA interference/gene knockdown; Bioanalysis of biologics for nucleic acid content | |||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
Indicative Reading List
| |||||||||||||||||||||||||||||||||||||||||||
|
Other Resources None | |||||||||||||||||||||||||||||||||||||||||||